Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer's decision to license SSGJ-707 doesn't make its stock a buy in and of itself. However, the drug candidate is another valuable asset that will be part of the company's plan to improve its ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average dividend payer in the S&P 500.If it can't maintain its payout-raising streak ...

Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces. Last year, Pfizer's COVID-19 vaccine Comirnaty generated sales of $5.35 billion.

Shares of Pfizer Inc. PFE slipped 2.04% to $23.04 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.61% to 5,844.61 and ...